About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Biomedical Research Group in Gynaecology is a multidisciplinary team made up of clinical specialists in gynaecology and pathology and basic and translational researchers. Our research is clearly translational. Although we take into account the obvious importance of understanding the mechanism at the cellular and molecular level and try to incorporate it into our research, our research is always focused on having a direct applicability to patients and their clinical benefit. On our way to transferring scientific results to clinical practice, we promote innovation and entrepreneurship.
Our group comprises four main research groups, which are closely connected: The clinical research group devoted mainly to clinical projects in all gynaecological cancers; and three translational research groups dedicated to ovarian cancer; endometrial cancer and endometriosis; diseases of the lower female genital tract.
IP: Valeria Tubita Collaborators: - Funding agency: Fundació Santiago Dexeus Font Funding: 6000 Reference: DEXEUS/PROJECTE/TUBITA/2024 Duration: 30/12/2024 - 30/12/2026
IP: Vicente Bebia Conesa Collaborators: Maria Asuncion Perez Benavente, Francesc Xavier Serra Marin, Antonio Gil Moreno, Martina Angeles Fite, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Melissa Bradbury Lobato, Melek Denizli , Telemedicine-guided Patients Reported Outcome Measures (PROMs): side efects screening and early intervention to impact in qualit Funding agency: Fundació La Marató de TV3 Funding: 96737.5 Reference: 202403-30 Duration: 28/02/2025 - 27/02/2028
IP: Eva Colas Ortega Collaborators: Elena Suarez Salvador, Francesc Xavier Serra Marin, Carina Masferrer Ferragutcasas, Anna Ruano Lopez, Josep Castellví Vives, Sonia Monreal Clua, Diana Alejandra Guerrero Lojano, Raquel Delgado Gil Funding agency: Fundació La Marató de TV3 Funding: 200000 Reference: 202407-10 Duration: 20/02/2025 - 19/02/2028
IP: Antonio Gil Moreno Collaborators: Vicente Bebia Conesa, Francesc Xavier Serra Marin, Marta Rebull Santamaria, Martina Angeles Fite, Melissa Bradbury Lobato, Lourdes Elena Salazar Huayna, Beatriz Villafranca Magdalena, Melek Denizli , Valeria Tubita Funding agency: Instituto de Salud Carlos III Funding: 196250 Reference: PI24/01509 Duration: 01/01/2025 - 31/12/2027
PhD student: Eva Coll De la Rubia Director/s: Antonio Gil Moreno, Silvia Cabrera Diaz, Eva Colas Ortega University: Universidad Autònoma de Barcelona Year: 2022
PhD student: Antonio Jesús Esgueva Colmenarejo Director/s: Antonio Gil Moreno, Isabel Teresa Rubio Rodríguez University: Universidad Autònoma de Barcelona Year: 2017
The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies
The study evaluated the results of combining SYD985, a HER2 antibody conjugated to a potent cytotoxic drug, and niraparib, an inhibitor of DNA damage repair.
Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.
